On-demand sildenafil for exercise capacity in pulmonary arterial hypertension
Treatments studied
Part of Lungs & breathing clinical trials.
This trial tests whether taking sildenafil (a medicine that helps relax blood vessels) on demand, compared to a sugar candy placebo, can improve exercise capacity in people with pulmonary arterial hypertension (PAH). Participating may help you exercise more easily and contribute to better treatment options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have been diagnosed with pulmonary arterial hypertension (PAH) using a right heart catheterization test.
- Your PAH symptoms are stable, and you have been on the same PAH medication for more than 4 weeks.
- You do not have severe lung disease, like advanced COPD or pulmonary fibrosis.
- You are not taking certain medications that could interact with the study drug, such as nitrates (e.g., nitroglycerin), riociguat, or strong CYP3A4 inhibitors (e.g., some antifungals or antibiotics).
- You are not pregnant or breastfeeding, and you have no known allergies to sildenafil or dextrose candy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests whether sildenafil tablets can improve exercise ability, shortness of breath, and heart-lung function in people with COPD. It also compares against people without COPD to better understand how sildenafil affects breathing tests.
This study compares two approaches for people with PAH whose current treatment (a combination of sildenafil and an endothelin receptor antagonist) needs to be stepped up. Half the participants will add a third medicine (iloprost or selexipag), while the other half will increase their sildenafil dose. The goal is to see which strategy works better for improving symptoms and lowering risk.
This trial tests an investigational drug called NS-863 for people with pulmonary arterial hypertension (PAH), a condition of high blood pressure in the lungs. The study aims to see if the drug can improve symptoms and exercise ability.
This trial tests whether adding the study drug sotatercept to your current PAH therapy along with a home exercise program can help you feel better and be more active. It's for people with certain types of PAH who are stable on their current treatment.
This trial tests an experimental drug called HS235 for people with pulmonary arterial hypertension (PAH), a condition of high blood pressure in the lungs. It aims to see if the drug can help improve symptoms and exercise ability.
This trial tests whether an inhaled medication called treprostinil (which helps open blood vessels in the lungs) can improve exercise ability in people who get high blood pressure in the lungs only during exercise. Participation involves taking the medication and doing exercise tests to see how well you do.
Hear when a new Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.